Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs International Business Machines Corp (IBM) Price & Performance

Gilead Sciences, Inc.Trade
International Business Machines CorpTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs International Business Machines Corp — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while International Business Machines Corp trades at $237.42 (market cap $222.64B). The key difference: International Business Machines Corp is the larger of the two by market cap, and International Business Machines Corp pays the higher dividend (2.86%). Which is the better fit depends on your goals.

GILDIBM
Market Cap
$164.99B$222.64B
Sector
HealthTechnology
52-Week High
$155.80$329.23
52-Week Low
$110.56$205.77
Enterprise Value
$188.06B$279.78B
Dividend Yield
2.47%2.86%
Volume
4,481,527

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

International Business Machines Corp

IBM trades at $237.28, up 1.65% today, with a mixed technical outlook showing bullish overall signals but bearish momentum indicators. Recent earnings beat expectations in Q1 2026, though Q2 2026 matched estimates, and revenue growth accelerated to $67.54 billion in 2025. The company maintains strong profitability with a net income margin of 15.52% and a dividend yield of approximately 2.8%, supported by positive cash flow from operations of $13.19 billion.

The stock offers a balanced risk-reward profile, with a consensus price target of $257.38 implying 8.5% upside, but faces headwinds from a securities fraud investigation and competitive pressures in AI. Long-term growth hinges on quantum computing and hybrid cloud adoption, yet near-term volatility may persist due to legal uncertainties and macroeconomic factors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About International Business Machines Corp

International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.

Read more on IBM